Eledon Pharmaceuticals, Inc. ELDN
Set alert
2.61 USD -0.01 -0.38%
As of Nov 3, 2:28 PM ET
2.58 Day range 2.75
1.35 52-week range 4.49
- YTD
- +72.85%
- 1 year
- -40.14%
- Open
- 2.62
- Prev close
- 2.62
- Mkt cap
- 212.09M
- Vol
- 198.05K
- Avg vol
- 920.79K
- EPS
- -0.90
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.58
- High
- 2.75
- Forward P/E
- -3.49
- Beta
- 0.00
- Short ratio
- 0.75
- Inst. own
- 42.88%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.12
- 200-d avg
- 2.88
- 1y target
- 12.50
3M chart
Signals (18)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Sep 9, 2026 | 1 month ago |
| RSI: Oversold | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
Analyst view
Price target (mean) 12.50 +378.9% upside
Now 2.61
- Target (low)
- 7.00
- Target (mean)
- 12.50
- Target (high)
- 20.50
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.30333 | -0.37 – -0.16 | -0.29 | -4.6% | 0 | 0.0% | 4 |
| Next quarter | -0.28 | -0.28 – -0.28 | -0.34 | +17.6% | 0 | 0.0% | 1 |
| Current year | -1.34 | -2.77 – -0.28 | -1.64 | +18.3% | 0 | 0.0% | 5 |
| Next year | -0.93 | -1.12 – -0.76 | -1.34 | +30.6% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 27, 2023 | Noble Capital Markets | Initiated | — | Outperform |
| Aug 22, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| May 26, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 1, 2022 | SVB Leerink | Maintained | — | Outperform |
| Nov 24, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 27, 2021 | SVB Leerink | Maintained | — | Outperform |
| Mar 23, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Feb 8, 2021 | SVB Leerink | Initiated | — | Outperform |